Condition: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation · Metastatic Prostate Neuroendocrine Carcinoma · Metastatic Prostate Small Cell Neuroendocrine Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both hormone-producing endocrine cells and nerve cells. These cells release hormones into the blood in response to a signal from the nervous system. Hormones are biological substances that circulate through the bloodstream to control the activity of other organs or cells in the body. Lutetium Lu 177-dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Treatment with Lutetium Lu 177 dotatate may shrink the tumor in a way that can be measured in patients with metastatic prostate cancer with neuroendocrine differentiation.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| Los Angeles General Medical Center | Los Angeles, California, United States | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Active Not Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Kentucky/Markey Cancer Center | Lexington, Kentucky, United States | Recruiting |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Wake Forest University Health Sciences | Winston-Salem, North Carolina, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas, Texas, United States | Suspended |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison, Wisconsin, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05691465